#22 – The Future of Cancer Detection – And the Start-Up Fighting to Make It Real

What if cancer could be detected before it even starts showing symptoms? This episode dives into the bold vision of turning that “what if” into reality and shares what it really takes to building up a life science start-up from scientific breakthroughs to navigating bureaucracy. In this episode of Talking Life Science, we speak with Maximilian Schneider, co-founder and CTO of Wholomics, about a mission that is both deeply personal and scientifically groundbreaking: enabling early cancer detection through innovative multi-omics blood tests. Hosted by Ivan Orban, Senior Teamleader at the Aristo Group in Austria, this conversation explores not only the vision behind Wholomics but also the real-world challenges that come with building a life science start-up from complex regulatory landscapes and fragmented healthcare systems to funding struggles and navigating the European biotech ecosystem. Maximilian Schneider shares valuable insights and lessons learned for other founders: why simplicity beats over-engineering, how to focus on what truly matters to patients, and why perseverance and the right partners are essential for success in this highly demanding field. At its core, this episode is about more than just technology – it's about turning a dream into reality, improving lives through prevention and staying resilient in the face of systemic challenges. A must-listen for anyone shaping the future of healthcare innovation. Guest: Maximilian Schneider, Co-Founder and CTO, Wholomics Host: Ivan Orban, Senior Team Leader at the Aristo Group in Austria